Proliferating cell nuclear antigen in epithelial ovarian cancer: relation to results at second-look laparotomy and survival.
We determined the proliferative index (PI) of 92 previously untreated advanced epithelial ovarian cancers using PCNA/cyclin immunostaining and image analysis quantitation. In this retrospective study, there was a relationship between tumor PI and 5-year survival. For patients with a tumor PI greater than the median, the estimated 5-year survival was 44%; for patients with a tumor PI below the median, the estimated 5-year survival was 15% (P = 0.003). This may partly reflect sensitivity to chemotherapy, as those patients with more rapidly proliferating tumors were more likely to achieve a pathologic complete response to platinum-based therapy.
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905.
L C
LC
Hartmann
T J
TJ
Sebo
N A
NA
Kamel
K C
KC
Podratz
S S
SS
Cha
H S
HS
Wieand
G L
GL
Keeney
P C
PC
Roche
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D002277:Carcinoma / Q000737:chemistry* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009687:Nuclear Proteins / Q000032:analysis*; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000601:surgery; D018809:Proliferating Cell Nuclear Antigen; D016016:Proportional Hazards Models; D012086:Reoperation; D012189:Retrospective Studies; D016019:Survival Analysis
D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen